Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001520
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
The Early Reversibility of Rocuronium After Different Doses of Neostigmine
Sponsor:
National Institutes of Health Clinical Center CC
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
The Early Reversibility of Rocuronium After Different Doses of Neostigmine
Status:
COMPLETED
Status Verified Date:
1999-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neuromuscular blocking agents are commonly used to facilitate endotracheal intubation Succinylcholine an ultra short-acting depolarizing neuromuscular blocking agent is the most commonly used agent for paralysis in this setting because of its rapid onset and short duration of paralysis In patients with contraindications to succinylcholine or in whom a difficult airway is anticipated a neuromuscular blocking agent with a pharmacodynamic profile similar to succinylcholine would be an attractive alternative Rocuronium a new intermediate-acting nondepolarizing neuromuscular blocking agent produces paralysis within 60 seconds similar to succinylcholine but has a duration of paralysis of approximately 20 to 30 minutes If rocuronium-induced paralysis could be chemically reversed within 10 to 15 minutes after the administration of an intubating dose it may be an appropriate alternative in patients with contraindications to succinylcholine or in patients whom a difficult airway is anticipated Neostigmine is an anticholinesterase agent which inhibits the hydrolysis of acetylcholine by competing with acetylcholine for attachment to acetylcholinesterase Inhibition of the breakdown of acetylcholine allows the neurotransmitter to be present in the neuromuscular junction for a longer period of time so that each molecule can bind repeatedly with the acetylcholine receptor The purpose of this study is to determine the dose of neostigmine necessary for the early reversal of rocuronium-induced paralysis
Detailed Description:
Neuromuscular blocking agents are commonly used to facilitate endotracheal intubation Succinylcholine an ultra short-acting depolarizing neuromuscular blocking agent is the most commonly used agent for paralysis in this setting because of its rapid onset and short duration of paralysis In patients with contraindications to succinylcholine or in whom a difficult airway is anticipated a neuromuscular blocking agent with a pharmacodynamic profile similar to succinylcholine would be an attractive alternative Rocuronium a new intermediate-acting nondepolarizing neuromuscular blocking agent produces paralysis within 60 seconds similar to succinylcholine but has a duration of paralysis of approximately 20 to 30 minutes If rocuronium-induced paralysis could be chemically reversed within 10 to 15 minutes after the administration of an intubating dose it may be an appropriate alternative in patients with contraindications to succinylcholine or in patients whom a difficult airway is anticipated Neostigmine is an anticholinesterase agent which inhibits the hydrolysis of acetylcholine by competing with acetylcholine for attachment to acetylcholinesterase Inhibition of the breakdown of acetylcholine allows the neurotransmitter to be present in the neuromuscular junction for a longer period of time so that each molecule can bind repeatedly with the acetylcholine receptor The purpose of this study is to determine the dose of neostigmine necessary for the early reversal of rocuronium-induced paralysis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 96-CC-0122 | None | None | None |